Journey Medical stock fell 7.92 percent as Q2 revenue grew 23 percent

Published on 10/07/2026 at 01:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Journey Medical stock was last at USD 6.16 on October 6, 2026, after a 7.92 percent daily drop. Q2 revenue reached USD 18.51 million, up 23 percent year over year.

DERM, US48115J1097, Illustration mit AI erstellt.

Journey Medical Corporation stock (ISIN US48115J1097) was last at USD 6.16 on Nasdaq on October 6, 2026, after falling 7.92 percent in the session. The move came against Q2 2026 revenue of USD 18.51 million, up 23 percent from the prior-year quarter.

Q2 revenue climbed 23 percent

Journey Medical's second-quarter figures show a business growing faster than its share price on the latest session. According to Quartr in its September 10, 2026 earnings summary, revenue rose from USD 15.0 million in Q2 2025 to USD 18.5 million in Q2 2026, a 23 percent increase.

The improvement also reached the bottom line. Q2 GAAP net loss narrowed to USD 312,000, or USD 0.01 per diluted share, from USD 3.8 million, or USD 0.16 per share, in the prior-year quarter, while gross margin stood at 67 percent, according to Quartr.

Analyst targets stay above USD 13

The valuation gap remains the central market question. MarketBeat reported on October 3, 2026, that four analysts split between two Buy ratings, one Hold and one Sell, producing a Hold consensus and an average price target of USD 14.00. Against the USD 6.16 price on October 6, 2026, that target lies 127.3 percent above the stock.

Markets Insider reported on September 22, 2026, that H.C. Wainwright maintained a Buy rating and set a USD 13.00 target. MarketBeat separately reported that B. Riley raised its target from USD 12.00 to USD 15.00 on August 13, 2026.

Cash and profitability remain key

Journey Medical ended Q2 2026 with USD 25.6 million in cash and cash equivalents, according to Quartr. The same summary cites positive non-GAAP EBITDA of USD 1.4 million and adjusted EBITDA of USD 2.9 million for the quarter, but it also notes substantial doubt about the company's ability to continue as a going concern for at least twelve months.

Journey Medical Corporation describes its business as the acquisition and commercialization of differentiated dermatology products. Its latest investor-relations page identifies Q2 2026, the quarter ended June 30, 2026, as the latest financial-results period.

Stock remains below yearly high

Journey Medical stock was last at USD 6.16 on Nasdaq on October 6, 2026, with a session range of USD 6.13 to USD 6.77. Its 52-week range was USD 4.31 to USD 9.56, while market capitalization stood at USD 169.5 million and volume reached 205,027 shares.